sarepta therapeutics vinay prasad - Search News

News

Inside fall of Vinay Prasad at FDA

Mint on MSN · 2d

Who is Vinay Prasad? US FDA's top regulator exits agency after controversy over Sarepta gene therapy

Dr Vinay Prasad has resigned from the FDA after less than three months amid controversy over Sarepta Therapeutics' gene therapy and pressure from the White House. He plans to return to California to spend more time with his family.

PharmExec · 2d

Vinay Prasad’s FDA Departure Follows Controversy Over Drug Rejections

The FDA’s top vaccine and gene therapy official resigned amid heightened scrutiny over recent drug approval decisions and safety concerns surrounding gene therapies.

Vinay Prasad was not good for the FDA. But his ouster makes things worse

Vinay Prasad’s three-month tenure as one of the top officials at the Food and Drug Administration was bad for medicine. But his forced departure is probably worse.

2d

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

2don MSN

Sarepta, Replimmune, Capricor rise as FDA’s biologics head departs

Replimune (NASDAQ:REPL), and Capricor Therapeutics (NASDAQ:CAPR), which faced regulatory setbacks from the FDA’s biologics ...

Report Says President Trump Pushed for Vinay Prasad’s Removal

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results